GoAI
Get started
Cardiff Oncology, Inc. logo

Cardiff Oncology, Inc.

CRDF

NASDAQHealthcareBiotechnology

Open in GoAI

Previous close

$0.8801

−$0.0286 · -3.15%

Aug 21, 4:00 PM ET

Pre-market

$0.8897

+$0.0096 · +1.09%

Aug 24, 4:01 AM ET

CRDF company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Sell

Trim exposure — unfavorable risk-reward

Valuation

7

Overpriced

Momentum

21

Weakening

Sentiment

64

Bullish

Risk resilience

28

High Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies for the treatment of various cancers in the United States. Its lead drug candidate is Onvansertib, an oral and selective polo-like kinase 1 inhibitor for treating RAS-mutated metastatic colorectal cancer. The company also focuses on the clinical program in indications, such as investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma, small cell lung cancer, metastatic triple negative breast cancer, and chronic myelomonocytic leukemia; CRDF-004, a Phase 2 open-label randomized multi-center clinical trial of onvansertib in combination with FOLFIRI and bevacizumab or FOLFOX and bevacizumab for the treatment of patients confirmed metastatic and unresectable colorectal cancer in patients with a KRAS or NRAS mutation; and TROV-054, a Phase 1b/2 single-arm clinical trial in KRAS-mutated metastatic colorectal cancer. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was founded in 1999 and is headquartered in San Diego, California.

Industry
Biotechnology
Sector
Healthcare
Headquarters
US
CEO
Mani Mohindru
Listed since
Jul 27, 2004
Employees
31

Market position

Day range

Current $0.8801

52-week range

Current $0.8801

Open
$0.92
Previous close
$0.9087
Volume
653.49K
0.51× average
Average volume
1.28M
Average daily volume
Market cap
67.83M USD
Beta
1.44
Market reference 1
50-day average
$1.082
-18.66% below average
200-day average
$1.777
-50.47% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
171.19M USD
P/E (TTM)
-1.47×
P/B (TTM)
2.27×
P/S (TTM)
133.53×
EV / EBITDA
-3.81×
Earnings yield
-24.41%
Free cash flow yield
-20.21%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
100.00%
Operating margin
-8320.08%
Net margin
-7884.06%
Return on equity
-101.02%
Return on assets
-74.09%
Return on invested capital
-105.93%

Financial health

Debt / equity
0.02×
Current ratio
3.67×

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends1144%-3031%-7206%-11381%Gross margin, FY2021: 100.00%Gross margin, FY2022: 100.00%Gross margin, FY2023: 100.00%Gross margin, FY2024: 100.00%Gross margin, FY2025: 100.00%Operating margin, FY2021: -8037.60%Operating margin, FY2022: -10337.31%Operating margin, FY2023: -9305.74%Operating margin, FY2024: -7123.13%Operating margin, FY2025: -8256.32%Net margin, FY2021: -7880.50%Net margin, FY2022: -10026.94%Net margin, FY2023: -8492.01%Net margin, FY2024: -6651.68%Net margin, FY2025: -7732.04%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 100.00%. Gross margin FY2022 100.00%. Gross margin FY2023 100.00%. Gross margin FY2024 100.00%. Gross margin FY2025 100.00%. Operating margin FY2021 -8037.60%. Operating margin FY2022 -10337.31%. Operating margin FY2023 -9305.74%. Operating margin FY2024 -7123.13%. Operating margin FY2025 -8256.32%. Net margin FY2021 -7880.50%. Net margin FY2022 -10026.94%. Net margin FY2023 -8492.01%. Net margin FY2024 -6651.68%. Net margin FY2025 -7732.04%.

Income trends

Revenue

593K USD-13.18%

Operating income

−48.96M USD-0.64%

Net income

−45.85M USD-0.92%
Income trends across reported periods5.65M USD−14.21M USD−34.07M USD−53.92M USDRevenue, FY2021: 359K USDRevenue, FY2022: 386K USDRevenue, FY2023: 488K USDRevenue, FY2024: 683K USDRevenue, FY2025: 593K USDOperating income, FY2021: −28.86M USDOperating income, FY2022: −39.9M USDOperating income, FY2023: −45.41M USDOperating income, FY2024: −48.65M USDOperating income, FY2025: −48.96M USDNet income, FY2021: −28.29M USDNet income, FY2022: −38.7M USDNet income, FY2023: −41.44M USDNet income, FY2024: −45.43M USDNet income, FY2025: −45.85M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 359K USD. Revenue FY2022 386K USD. Revenue FY2023 488K USD. Revenue FY2024 683K USD. Revenue FY2025 593K USD. Operating income FY2021 −28.86M USD. Operating income FY2022 −39.9M USD. Operating income FY2023 −45.41M USD. Operating income FY2024 −48.65M USD. Operating income FY2025 −48.96M USD. Net income FY2021 −28.29M USD. Net income FY2022 −38.7M USD. Net income FY2023 −41.44M USD. Net income FY2024 −45.43M USD. Net income FY2025 −45.85M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue593K USD683K USD488K USD386K USD359K USD
Gross profit593K USD683K USD488K USD386K USD359K USD
Research and development35.33M USD36.85M USD32.86M USD27.11M USD17.38M USD
Selling, general, and administrative14.22M USD12.48M USD13.04M USD13.18M USD11.84M USD
Operating expenses49.55M USD49.33M USD45.9M USD40.29M USD29.21M USD
Interest income3.1M USD3.26M USD4.07M USD1.58M USD264K USD
Depreciation and amortization904K USD404K USD398K USD236K USD451K USD
Operating income−48.96M USD−48.65M USD−45.41M USD−39.9M USD−28.86M USD
Net income−45.85M USD−45.43M USD−41.44M USD−38.7M USD−28.29M USD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
55%
6 beats, 5 misses, 0 met estimates
Average EPS surprise
+3.32%
11 comparable reports
Latest EPS result
-0.14
Estimate -0.12 · Miss by 17.03%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates-0.09-0.16-0.23-0.3Q1 '25BeatQ2 '25MissQ3 '25MissQ4 '25BeatQ1 '26BeatQ2 '26MissQ3 '26MissQ4 '26Estimate
Q1 2025, reported Feb 27, 2025: actual -0.21, estimate -0.26, surprise +19.23%, Beat. Q2 2025, reported May 8, 2025: actual -0.2, estimate -0.19, surprise -5.26%, Miss. Q3 2025, reported Jul 29, 2025: actual -0.21, estimate -0.19, surprise -10.53%, Miss. Q4 2025, reported Nov 6, 2025: actual -0.17, estimate -0.2, surprise +15.00%, Beat. Q1 2026, reported Feb 24, 2026: actual -0.11, estimate -0.18, surprise +38.89%, Beat. Q2 2026, reported May 14, 2026: actual -0.18, estimate -0.13, surprise -38.46%, Miss. Q3 2026, reported Aug 11, 2026: actual -0.14, estimate -0.12, surprise -17.03%, Miss. Q4 2026, reported Nov 5, 2026: actual —, estimate -0.15, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates259.16K184.39K109.62K34.85KQ1 '25BeatQ2 '25BeatQ3 '25BeatQ4 '25BeatQ1 '26BeatQ2 '26MissQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Feb 27, 2025: actual 151K USD, estimate 94.17K USD, surprise +60.35%, Beat. Q2 2025, reported May 8, 2025: actual 109K USD, estimate 89.29K USD, surprise +22.07%, Beat. Q3 2025, reported Jul 29, 2025: actual 121K USD, estimate 109.38K USD, surprise +10.63%, Beat. Q4 2025, reported Nov 6, 2025: actual 120K USD, estimate 103.5K USD, surprise +15.94%, Beat. Q1 2026, reported Feb 24, 2026: actual 243K USD, estimate 103.5K USD, surprise +134.78%, Beat. Q2 2026, reported May 14, 2026: actual 41K USD, estimate 88.57K USD, surprise -53.71%, Miss. Q3 2026, reported Aug 11, 2026: actual 104K USD, estimate 62.78K USD, surprise +65.66%, Beat. Q4 2026, reported Nov 5, 2026: actual —, estimate 67.22K USD, surprise —, Comparison unavailable.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Rating distribution

15 ratings
Strong buy00%
Buy747%
Hold747%
Sell17%
Strong sell00%

Recent analyst actions

5 institutions
William BlairdowngradeOutperformMarket Perform
Craig-HallumdowngradeBuyHold
TD CowendowngradeBuyHold

CRDF news

globenewswire.com

Cardiff Oncology Reports Second Quarter 2026 Results and Provides Business Update

Positive Phase 2 CRDF-004 data presented in an oral session at ASCO support advancement of 30 mg onvansertib plus FOLFIRI/bevacizumab into planned registrational program for first-line RAS-mutated mCRC

Read source
globenewswire.com

Cardiff Oncology Announces $10 Million Registered Direct Offering

SAN DIEGO, July 15, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF) (the “Company”), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel cancer therapies, today announced…

Read source
seekingalpha.com

Cardiff Oncology, Inc. (CRDF) Discusses Updated Phase II CRDF-004 Data on Onvansertib in First-Line RAS-Mutated Metastatic Colorectal Cancer Transcript

Cardiff Oncology, Inc. (CRDF) Discusses Updated Phase II CRDF-004 Data on Onvansertib in First-Line RAS-Mutated Metastatic Colorectal Cancer Transcript

Read source
globenewswire.com

Cardiff Oncology Announces Presentation of Positive Results from its Randomized, Controlled Phase 2 Trial of Onvansertib in First-Line RAS-Mutated mCRC at the 2026 ASCO Annual Meeting

-​ The trial achieved its primary goal of selecting the efficacious and safe dose of onvansertib + standard-of-care (SoC) regimen for the registrational program -​

Read source
globenewswire.com

Cardiff Oncology to Participate in the Jefferies Global Healthcare Conference

SAN DIEGO, June 01, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced…

Read source

CRDF peers

Amgen Inc. logo

AMGN

Amgen Inc.

$439.33

+1.29%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$146.12

+1.87%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$548.05

+1.44%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$378.81

+1.16%

Sanofi logo

SNY

Sanofi

$45.85

+1.55%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$834.04

+0.90%

ETFs holding CRDF

Funds reporting this stock among their holdings, ordered by reported position size.

Vanguard Morningstar Total Stock Market ETF logoVanguard Morningstar Total Stock Market ETFVTI
Market value
1.77M
Weight
0.00%
AUM
2.3T USD
Expense ratio
0.03%
Price / 1D
$378.24+0.44%
Vanguard Extended Market ETF logoVanguard Extended Market ETFVXF
Market value
649.52K
Weight
0.00%
AUM
93.7B USD
Expense ratio
0.05%
Price / 1D
$245.53+0.82%
iShares Micro-Cap ETF logoiShares Micro-Cap ETFIWC
Market value
204.1K
Weight
0.01%
AUM
1.53B USD
Expense ratio
0.60%
Price / 1D
$198.39+1.10%

Continue in GoAI

Research CRDF

research.disclaimer